However, several unresolved issues, including (1) whether other potential PTX3 receptor contribute to PTX3-mediated protumor effects, (2) whether WHC-001 disrupts other potential PTX3 receptor interactions and (3) whether CD44 is the critical factor in the switch between the anti- and protumor role of PTX3 in colon cancer progression, remain to be further investigated. The gene discussed is CD44; the disease is malignant colon neoplasm.